Your browser doesn't support javascript.
loading
In vitro and in vivo evaluation of the biofilm-degrading Pseudomonas phage Motto, as a candidate for phage therapy.
Manohar, Prasanth; Loh, Belinda; Turner, Dann; Tamizhselvi, Ramasamy; Mathankumar, Marimuthu; Elangovan, Namasivayam; Nachimuthu, Ramesh; Leptihn, Sebastian.
Afiliación
  • Manohar P; School of Bioscience and Technology, Vellore Institute of Technology (VIT), Vellore, India.
  • Loh B; Department of Vaccines and Infection Models, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
  • Turner D; School of Applied Sciences, College of Health, Science and Society, University of the West of England, Bristol, United Kingdom.
  • Tamizhselvi R; School of Bioscience and Technology, Vellore Institute of Technology (VIT), Vellore, India.
  • Mathankumar M; School of Bioscience and Technology, Vellore Institute of Technology (VIT), Vellore, India.
  • Elangovan N; Department of Biotechnology, School of Bioscience, Periyar University, Salem, Tamil Nadu, India.
  • Nachimuthu R; School of Bioscience and Technology, Vellore Institute of Technology (VIT), Vellore, India.
  • Leptihn S; Department of Biochemistry, Health and Medical University, Erfurt, Germany.
Front Microbiol ; 15: 1344962, 2024.
Article en En | MEDLINE | ID: mdl-38559352
ABSTRACT
Infections caused by Pseudomonas aeruginosa are becoming increasingly difficult to treat due to the emergence of strains that have acquired multidrug resistance. Therefore, phage therapy has gained attention as an alternative to the treatment of pseudomonal infections. Phages are not only bactericidal but occasionally show activity against biofilm as well. In this study, we describe the Pseudomonas phage Motto, a T1-like phage that can clear P. aeruginosa infections in an animal model and also exhibits biofilm-degrading properties. The phage has a substantial anti-biofilm activity against strong biofilm-producing isolates (n = 10), with at least a twofold reduction within 24 h. To demonstrate the safety of using phage Motto, cytotoxicity studies were conducted with human cell lines (HEK 293 and RAW 264.7 macrophages). Using a previously established in vivo model, we demonstrated the efficacy of Motto in Caenorhabditis elegans, with a 90% survival rate when treated with the phage at a multiplicity of infection of 10.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Microbiol Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Microbiol Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Suiza